---
document_datetime: 2025-12-02 05:25:10
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/cinqaero.html
document_name: cinqaero.html
version: success
processing_time: 0.114111
conversion_datetime: 2025-12-26 17:35:42.647215
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Cinqaero

[RSS](/en/individual-human-medicine.xml/66753)

##### Authorised

This medicine is authorised for use in the European Union

reslizumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Cinqaero](#news-on)
- [More information on Cinqaero](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Cinqaero. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Cinqaero.

For practical information about using Cinqaero, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Cinqaero and what is it used for?

Cinqaero is an asthma medicine that is used to treat adults with a particular type of asthma called eosinophilic asthma. It is used as an additional treatment in adults with severe asthma that is not properly controlled by a combination of high-dose corticosteroids taken by inhalation plus another medicine used for the prevention of asthma. The medicine contains the active substance reslizumab.

## How is Cinqaero used?

Cinqaero can only be obtained with a prescription and should be prescribed by doctors with experience in the treatment of eosinophilic asthma. It is available as a concentrate for making a solution for infusion (drip) into a vein. The recommended dose is 3 mg for each kg of bodyweight. The infusion should be given once every four weeks, for as long as the patient is considered to benefit, and doctors should re-assess at least once a year whether treatment should be continued. For further information, see the package leaflet.

## How does Cinqaero work?

In eosinophilic asthma, symptoms are associated with having too many of a type of white blood cell called eosinophils in the blood and in phlegm in the lungs. The active substance in Cinqaero, reslizumab, is a monoclonal antibody designed to attach to a substance called interleukin-5, which stimulates the growth and activity of eosinophils. By attaching to interleukin-5 and blocking its activity, Cinquaero reduces the number of eosinophils in the blood and lungs. This helps to reduce inflammation, resulting in a reduction in asthma attacks and improvement of symptoms.

## What benefits of Cinqaero have been shown in studies?

The benefits of Cinqaero have been shown in two main studies involving 953 patients with eosinophilic asthma that was not well controlled by inhaled corticosteroids and other asthma medication used for the prevention of the disease. Cinqaero was compared with placebo (a dummy infusion), both given every 4 weeks for a year. The main measure of effectiveness was based on the number of flare-ups (exacerbations) of asthma during treatment. Flare-ups were seen in 32% of patients (151 out of 477) given Cinqaero compared with 50% (237 out of 476) of those given placebo. Additionally there was evidence of an improvement in lung function and asthma symptoms, and a decrease in number of eosinophils in the blood in patients given Cinqaero. Supportive data suggested that the benefit was maintained for up to two years.

## What are the risks associated with Cinqaero?

The most common side effect with Cinqaero (which may affect about 2 people in 100) is an increase in levels of the enzyme creatine phosphokinase in the blood (a measure of possible damage to muscles). Anaphylactic (severe allergic) reactions may affect less than 1 person in 100.

For the full list of all side effects and restrictions with Cinqaero, see the package leaflet.

## Why is Cinqaero approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Cinqaero's benefits are greater than its risks and recommended that it be approved for use in the EU. The reduction in flare-ups and improvement in lung function seen with Cinqaero were considered clinically relevant, particularly for patients who cannot be adequately controlled with high doses of inhaled corticosteroids and another medicine used for the prevention of asthma. Overall the medicine was well tolerated, and appropriate measures to monitor and manage risks have been put in place.

## What measures are being taken to ensure the safe and effective use of Cinqaero?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cinqaero have been included in the summary of product characteristics and the package leaflet.

## Other information about Cinqaero

The European Commission granted a marketing authorisation valid throughout the European Union for Cinqaero on 16 August 2016.

For more information about treatment with Cinqaero, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Cinqaero : EPAR - Summary for the public

English (EN) (93.87 KB - PDF)

**First published:** 02/09/2016

**Last updated:** 02/09/2016

[View](/en/documents/overview/cinqaero-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-841)

български (BG) (101.59 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/bg/documents/overview/cinqaero-epar-summary-public_bg.pdf)

español (ES) (74.21 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/es/documents/overview/cinqaero-epar-summary-public_es.pdf)

čeština (CS) (98.46 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/cs/documents/overview/cinqaero-epar-summary-public_cs.pdf)

dansk (DA) (72.9 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/da/documents/overview/cinqaero-epar-summary-public_da.pdf)

Deutsch (DE) (75.1 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/de/documents/overview/cinqaero-epar-summary-public_de.pdf)

eesti keel (ET) (72.19 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/et/documents/overview/cinqaero-epar-summary-public_et.pdf)

ελληνικά (EL) (101.55 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/el/documents/overview/cinqaero-epar-summary-public_el.pdf)

français (FR) (75.06 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/fr/documents/overview/cinqaero-epar-summary-public_fr.pdf)

hrvatski (HR) (93.83 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/hr/documents/overview/cinqaero-epar-summary-public_hr.pdf)

italiano (IT) (72.8 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/it/documents/overview/cinqaero-epar-summary-public_it.pdf)

latviešu valoda (LV) (95.61 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/lv/documents/overview/cinqaero-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (96.8 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/lt/documents/overview/cinqaero-epar-summary-public_lt.pdf)

magyar (HU) (94.07 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/hu/documents/overview/cinqaero-epar-summary-public_hu.pdf)

Malti (MT) (98.94 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/mt/documents/overview/cinqaero-epar-summary-public_mt.pdf)

Nederlands (NL) (74.25 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/nl/documents/overview/cinqaero-epar-summary-public_nl.pdf)

polski (PL) (100.39 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/pl/documents/overview/cinqaero-epar-summary-public_pl.pdf)

português (PT) (74.24 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/pt/documents/overview/cinqaero-epar-summary-public_pt.pdf)

română (RO) (94.93 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/ro/documents/overview/cinqaero-epar-summary-public_ro.pdf)

slovenčina (SK) (97.37 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/sk/documents/overview/cinqaero-epar-summary-public_sk.pdf)

slovenščina (SL) (91.94 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/sl/documents/overview/cinqaero-epar-summary-public_sl.pdf)

Suomi (FI) (72.33 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/fi/documents/overview/cinqaero-epar-summary-public_fi.pdf)

svenska (SV) (72.76 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

02/09/2016

[View](/sv/documents/overview/cinqaero-epar-summary-public_sv.pdf)

## Product information

Cinqaero : EPAR - Product Information

English (EN) (384.99 KB - PDF)

**First published:** 02/09/2016

**Last updated:** 11/04/2025

[View](/en/documents/product-information/cinqaero-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-400)

български (BG) (504.75 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/bg/documents/product-information/cinqaero-epar-product-information_bg.pdf)

español (ES) (394.4 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/es/documents/product-information/cinqaero-epar-product-information_es.pdf)

čeština (CS) (468.43 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/cs/documents/product-information/cinqaero-epar-product-information_cs.pdf)

dansk (DA) (390.76 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/da/documents/product-information/cinqaero-epar-product-information_da.pdf)

Deutsch (DE) (432.18 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/de/documents/product-information/cinqaero-epar-product-information_de.pdf)

eesti keel (ET) (377.82 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/et/documents/product-information/cinqaero-epar-product-information_et.pdf)

ελληνικά (EL) (493.83 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/el/documents/product-information/cinqaero-epar-product-information_el.pdf)

français (FR) (416.9 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/fr/documents/product-information/cinqaero-epar-product-information_fr.pdf)

hrvatski (HR) (469.5 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/hr/documents/product-information/cinqaero-epar-product-information_hr.pdf)

íslenska (IS) (383.78 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/is/documents/product-information/cinqaero-epar-product-information_is.pdf)

italiano (IT) (399.83 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/it/documents/product-information/cinqaero-epar-product-information_it.pdf)

latviešu valoda (LV) (474.69 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/lv/documents/product-information/cinqaero-epar-product-information_lv.pdf)

lietuvių kalba (LT) (461.28 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/lt/documents/product-information/cinqaero-epar-product-information_lt.pdf)

magyar (HU) (461.88 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/hu/documents/product-information/cinqaero-epar-product-information_hu.pdf)

Malti (MT) (481.69 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/mt/documents/product-information/cinqaero-epar-product-information_mt.pdf)

Nederlands (NL) (393.72 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/nl/documents/product-information/cinqaero-epar-product-information_nl.pdf)

norsk (NO) (383.15 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/no/documents/product-information/cinqaero-epar-product-information_no.pdf)

polski (PL) (486.32 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/pl/documents/product-information/cinqaero-epar-product-information_pl.pdf)

português (PT) (393.83 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/pt/documents/product-information/cinqaero-epar-product-information_pt.pdf)

română (RO) (489.38 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/ro/documents/product-information/cinqaero-epar-product-information_ro.pdf)

slovenčina (SK) (464.17 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/sk/documents/product-information/cinqaero-epar-product-information_sk.pdf)

slovenščina (SL) (443.43 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/sl/documents/product-information/cinqaero-epar-product-information_sl.pdf)

Suomi (FI) (393.68 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/fi/documents/product-information/cinqaero-epar-product-information_fi.pdf)

svenska (SV) (393.01 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

11/04/2025

[View](/sv/documents/product-information/cinqaero-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000261646 11/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Cinqaero : EPAR - All Authorised presentations

English (EN) (3.54 KB - PDF)

**First published:** 02/09/2016

**Last updated:** 05/02/2018

[View](/en/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-342)

български (BG) (38.79 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/bg/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_bg.pdf)

español (ES) (4.18 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/es/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_es.pdf)

čeština (CS) (18.29 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/cs/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (4.13 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/da/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (4.12 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/de/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (3.83 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/et/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (29.18 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/el/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_el.pdf)

français (FR) (4.07 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/fr/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (17.75 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/hr/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (4.12 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/is/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_is.pdf)

italiano (IT) (3.84 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/it/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (19.53 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/lv/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (18.01 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/lt/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (11.18 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/hu/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (18.85 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/mt/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (3.63 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/nl/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (4.03 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/no/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_no.pdf)

polski (PL) (18.85 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/pl/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_pl.pdf)

português (PT) (4.2 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/pt/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_pt.pdf)

română (RO) (18.55 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/ro/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (18.49 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/sk/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (10.81 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/sl/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (3.68 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/fi/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (4.19 KB - PDF)

**First published:**

02/09/2016

**Last updated:**

05/02/2018

[View](/sv/documents/all-authorised-presentations/cinqaero-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Cinqaero Active substance reslizumab International non-proprietary name (INN) or common name reslizumab Therapeutic area (MeSH) Asthma Anatomical therapeutic chemical (ATC) code R03DX08

### Pharmacotherapeutic group

Other systemic drugs for obstructive airway diseases

### Therapeutic indication

Cinqaero is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

## Authorisation details

EMA product number EMEA/H/C/003912 Marketing authorisation holder

Teva B.V.

Swensweg 5

Opinion adopted 22/06/2016 Marketing authorisation issued 15/08/2016 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Cinqaero : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.32 KB - PDF)

**First published:** 11/04/2025

[View](/en/documents/procedural-steps-after/cinqaero-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Cinqaero : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (224.83 KB - PDF)

**First published:** 22/05/2017

**Last updated:** 11/04/2025

[View](/en/documents/procedural-steps-after/cinqaero-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Cinqaero-H-C-3912-P46-011.1 : EPAR - Assessment Report

Adopted

Reference Number: EMA/494745/2019

English (EN) (430.22 KB - PDF)

**First published:** 12/09/2019

[View](/en/documents/variation-report/cinqaero-h-c-3912-p46-0111-epar-assessment-report_en.pdf)

Cinqaero-H-C-3912-P46-0008 : EPAR - Assessment Report

Adopted

Reference Number: EMA/847608/2018

English (EN) (2.02 MB - PDF)

**First published:** 19/02/2019

[View](/en/documents/variation-report/cinqaero-h-c-3912-p46-0008-epar-assessment-report_en.pdf)

Cinqaero-H-C-003912-P46-008 : EPAR - Assessment Report

Adopted

Reference Number: EMA/504083/2018

English (EN) (263.97 KB - PDF)

**First published:** 21/08/2018

**Last updated:** 21/08/2018

[View](/en/documents/variation-report/cinqaero-h-c-003912-p46-008-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Cinqaero : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/481610/2016

English (EN) (1.33 MB - PDF)

**First published:** 02/09/2016

**Last updated:** 02/09/2016

[View](/en/documents/assessment-report/cinqaero-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Cinqaero

Adopted

Reference Number: EMA/403687/2016

English (EN) (99.23 KB - PDF)

**First published:** 24/06/2016

**Last updated:** 24/06/2016

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-cinqaero_en.pdf)

#### News on Cinqaero

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2016) 24/06/2016

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0039120000) (initial marketing authorisation)

#### More information on Cinqaero

- [EMEA-001202-PIP02-13-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001202-pip02-13-m04)
- [Assessing the impact of remission at 12-months post-initiation of biologic therapy on long-term clinical outcomes of patients with severe asthma (SPOTLIGHT) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000789)
- [Sustainability of response to biologics in severe asthma and predictors of late failure among patients in an international registry (SHINE) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000788)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 11/04/2025

## Share this page

[Back to top](#main-content)